Skip to main content
main-content
Erschienen in: Der Gastroenterologe 6/2017

15.08.2017 | Kardiomyopathie | Schwerpunkt

Interaktionen von Leber und Herz

verfasst von: Dr. med. J. Kälsch, H. Kälsch, G. Gerken

Erschienen in: Die Gastroenterologie | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Leber und Herz sind durch Kreislauf und Stoffwechsel eng miteinander verbunden. Erkrankungen von Herz und Leber können das jeweils andere Organ beeinträchtigen. Sowohl in der akuten als auch in der chronischen Erkrankungsphase sind häufig beide Organe betroffen. Das metabolische Syndrom erhöht das Erkrankungsrisiko für beide Organe, bietet jedoch auch die Möglichkeit eines einheitlichen präventiven Ansatzes. Im klinischen Alltag sollte die enge Verbindung beider Organe interdisziplinäres Denken und Handeln veranlassen.
Literatur
1.
Zurück zum Zitat Eipel C, Abshagen K, Vollmar B (2010) Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J Gastroenterol 16(48):6046–6057 CrossRefPubMedPubMedCentral Eipel C, Abshagen K, Vollmar B (2010) Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J Gastroenterol 16(48):6046–6057 CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Fuhrmann V et al (2010) Hypoxic hepatitis – epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr 122(5–6):129–139 CrossRefPubMed Fuhrmann V et al (2010) Hypoxic hepatitis – epidemiology, pathophysiology and clinical management. Wien Klin Wochenschr 122(5–6):129–139 CrossRefPubMed
4.
Zurück zum Zitat Henrion J et al (2003) Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 82(6):392–406 CrossRef Henrion J et al (2003) Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 82(6):392–406 CrossRef
5.
Zurück zum Zitat Creteur J et al (2004) The hepatosplanchnic contribution to hyperlactatemia in endotoxic shock: effects of tissue ischemia. Shock 21(5):438–443 CrossRefPubMed Creteur J et al (2004) The hepatosplanchnic contribution to hyperlactatemia in endotoxic shock: effects of tissue ischemia. Shock 21(5):438–443 CrossRefPubMed
6.
Zurück zum Zitat Herzer K et al (2011) Onset of heart failure determines the hepatic cell death pattern. Ann Hepatol 10(2):174–179 PubMed Herzer K et al (2011) Onset of heart failure determines the hepatic cell death pattern. Ann Hepatol 10(2):174–179 PubMed
7.
Zurück zum Zitat Lee DH et al (2006) Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 27(18):2170–2176 CrossRefPubMed Lee DH et al (2006) Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28,838 middle-aged men and women. Eur Heart J 27(18):2170–2176 CrossRefPubMed
8.
Zurück zum Zitat Kazemi-Shirazi L et al (2007) Gamma glutamyltransferase and long-term survival: Is it just the liver? Clin Chem 53(5):940–946 CrossRefPubMed Kazemi-Shirazi L et al (2007) Gamma glutamyltransferase and long-term survival: Is it just the liver? Clin Chem 53(5):940–946 CrossRefPubMed
9.
Zurück zum Zitat Giallourakis CC, Rosenberg PM, Friedman LS (2002) The liver in heart failure. Clin Liver Dis 6(4):947–967 (viii–ix) CrossRefPubMed Giallourakis CC, Rosenberg PM, Friedman LS (2002) The liver in heart failure. Clin Liver Dis 6(4):947–967 (viii–ix) CrossRefPubMed
10.
Zurück zum Zitat Allen LA et al (2009) Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 11(2):170–177 CrossRefPubMedPubMedCentral Allen LA et al (2009) Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail 11(2):170–177 CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Gore RM et al (1994) Passive hepatic congestion: cross-sectional imaging features. AJR Am J Roentgenol 162(1):71–75 CrossRefPubMed Gore RM et al (1994) Passive hepatic congestion: cross-sectional imaging features. AJR Am J Roentgenol 162(1):71–75 CrossRefPubMed
12.
Zurück zum Zitat Parekh NK et al (2007) Elevated troponin I levels in acute liver failure: Is myocardial injury an integral part of acute liver failure? Hepatology 45(6):1489–1495 CrossRefPubMed Parekh NK et al (2007) Elevated troponin I levels in acute liver failure: Is myocardial injury an integral part of acute liver failure? Hepatology 45(6):1489–1495 CrossRefPubMed
13.
Zurück zum Zitat Pateron D et al (1999) Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 29(3):640–643 CrossRefPubMed Pateron D et al (1999) Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 29(3):640–643 CrossRefPubMed
14.
Zurück zum Zitat Henriksen JH et al (2003) Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52(10):1511–1517 CrossRefPubMedPubMedCentral Henriksen JH et al (2003) Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 52(10):1511–1517 CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Moller S, Henriksen JH (2002) Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 87(1):9–15 CrossRefPubMedPubMedCentral Moller S, Henriksen JH (2002) Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 87(1):9–15 CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Rayes N et al (1995) Cause of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralbl Chir 120(6):435–438 PubMed Rayes N et al (1995) Cause of death after liver transplantation: an analysis of 41 cases in 382 patients. Zentralbl Chir 120(6):435–438 PubMed
17.
Zurück zum Zitat Saner FH et al (2009) When the heart kills the liver: acute liver failure in congestive heart failure. Eur J Med Res 14:541–546 PubMedPubMedCentral Saner FH et al (2009) When the heart kills the liver: acute liver failure in congestive heart failure. Eur J Med Res 14:541–546 PubMedPubMedCentral
18.
Zurück zum Zitat Saner FH et al (2011) High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int 24(5):425–432 CrossRefPubMed Saner FH et al (2011) High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int 24(5):425–432 CrossRefPubMed
20.
Zurück zum Zitat Moller S, Henriksen JH (2008) Cardiovascular complications of cirrhosis. Gut 57(2):268–278 CrossRefPubMed Moller S, Henriksen JH (2008) Cardiovascular complications of cirrhosis. Gut 57(2):268–278 CrossRefPubMed
21.
Zurück zum Zitat Torregrosa M et al (2005) Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 42(1):68–74 CrossRefPubMed Torregrosa M et al (2005) Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 42(1):68–74 CrossRefPubMed
22.
Zurück zum Zitat Mohamed R et al (1996) Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 23(5):1128–1134 CrossRefPubMed Mohamed R et al (1996) Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 23(5):1128–1134 CrossRefPubMed
23.
Zurück zum Zitat Baars T et al (2016) In acute myocardial infarction liver parameters are associated with stenosis diameter. Medicine (Baltimore) 95(6):e2807 CrossRef Baars T et al (2016) In acute myocardial infarction liver parameters are associated with stenosis diameter. Medicine (Baltimore) 95(6):e2807 CrossRef
24.
Zurück zum Zitat Kim CH, Younossi ZM (2008) Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 75(10):721–728 CrossRefPubMed Kim CH, Younossi ZM (2008) Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 75(10):721–728 CrossRefPubMed
25.
Zurück zum Zitat Blachier M et al (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58(3):593–608 CrossRefPubMed Blachier M et al (2013) The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 58(3):593–608 CrossRefPubMed
26.
Zurück zum Zitat Adams LA et al (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129(1):113–121 CrossRefPubMed Adams LA et al (2005) The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129(1):113–121 CrossRefPubMed
27.
Zurück zum Zitat Wilkins T et al (2013) Nonalcoholic fatty liver disease: diagnosis and management. Am Fam Physician 88(1):35–42 PubMed Wilkins T et al (2013) Nonalcoholic fatty liver disease: diagnosis and management. Am Fam Physician 88(1):35–42 PubMed
28.
Zurück zum Zitat Ertle J et al (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128(10):2436–2443 CrossRefPubMed Ertle J et al (2011) Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 128(10):2436–2443 CrossRefPubMed
29.
Zurück zum Zitat Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363(14):1341–1350 CrossRefPubMed Targher G, Day CP, Bonora E (2010) Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 363(14):1341–1350 CrossRefPubMed
30.
Zurück zum Zitat Ozturk K et al (2015) Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men. Atherosclerosis 240(2):380–386 CrossRefPubMed Ozturk K et al (2015) Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men. Atherosclerosis 240(2):380–386 CrossRefPubMed
31.
Zurück zum Zitat Kälsch J et al (2015) Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Sci Rep 5:13058 CrossRefPubMedPubMedCentral Kälsch J et al (2015) Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Sci Rep 5:13058 CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Ding M et al (2014) Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 129(6):643–659 CrossRefPubMed Ding M et al (2014) Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 129(6):643–659 CrossRefPubMed
33.
Zurück zum Zitat Ruhl CE, Everhart JE (2005) Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 129(6):1928–1936 CrossRefPubMed Ruhl CE, Everhart JE (2005) Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 129(6):1928–1936 CrossRefPubMed
34.
Zurück zum Zitat Chen S et al (2014) Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol 29(3):435–441 CrossRefPubMed Chen S et al (2014) Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol 29(3):435–441 CrossRefPubMed
35.
Zurück zum Zitat Molloy JW et al (2012) Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55(2):429–436 CrossRefPubMed Molloy JW et al (2012) Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology 55(2):429–436 CrossRefPubMed
36.
Zurück zum Zitat Dunn W et al (2012) Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 57(2):384–391 CrossRefPubMedPubMedCentral Dunn W et al (2012) Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 57(2):384–391 CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Zein CO et al (2011) Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 54(4):753–759 CrossRefPubMed Zein CO et al (2011) Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 54(4):753–759 CrossRefPubMed
38.
Zurück zum Zitat Thompson S, Fraser RS, Barnden KL (1988) A beneficial effect of trypsin on the purification of turnip mosaic virus (TuMV) and other potyviruses. J Virol Methods 20(1):57–64 CrossRefPubMed Thompson S, Fraser RS, Barnden KL (1988) A beneficial effect of trypsin on the purification of turnip mosaic virus (TuMV) and other potyviruses. J Virol Methods 20(1):57–64 CrossRefPubMed
39.
Zurück zum Zitat Hickman IJ et al (2004) Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53(3):413–419 CrossRefPubMedPubMedCentral Hickman IJ et al (2004) Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 53(3):413–419 CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Berzigotti A, Saran U, Dufour JF (2016) Physical activity and liver diseases. Hepatology 63(3):1026–1040 CrossRefPubMed Berzigotti A, Saran U, Dufour JF (2016) Physical activity and liver diseases. Hepatology 63(3):1026–1040 CrossRefPubMed
41.
Zurück zum Zitat Berzigotti A et al (2017) Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology 65(4):1293–1305 CrossRefPubMed Berzigotti A et al (2017) Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. Hepatology 65(4):1293–1305 CrossRefPubMed
42.
Zurück zum Zitat Canbay A, Gerken G (Hrsg) (2017) Gastroenterologie für Intensivmediziner, Kapitel 5.3. Thieme, Stuttgart Canbay A, Gerken G (Hrsg) (2017) Gastroenterologie für Intensivmediziner, Kapitel 5.3. Thieme, Stuttgart
Metadaten
Titel
Interaktionen von Leber und Herz
verfasst von
Dr. med. J. Kälsch
H. Kälsch
G. Gerken
Publikationsdatum
15.08.2017
Verlag
Springer Medizin
Erschienen in
Die Gastroenterologie / Ausgabe 6/2017
Print ISSN: 2731-7420
Elektronische ISSN: 2731-7439
DOI
https://doi.org/10.1007/s11377-017-0193-x

Weitere Artikel der Ausgabe 6/2017

Der Gastroenterologe 6/2017 Zur Ausgabe

Mitteilungen der GARPS

Mitteilungen der GARPS

Mitteilungen der Stiftung LebensBlicke

Mitteilungen der Stiftung LebensBlicke

Passend zum Thema

ANZEIGE
sGC-Stimulation

Zusätzlicher Schutz für HF-Patienten nach Dekompensation

Trotz Basistherapien, die für die chronische Herzinsuffizienz mit reduzierter Ejektionsfraktion (HFrEF) zur Verfügung stehen, ist der Verlauf progredient und es kommt immer wieder zu akuten Dekompensationsereignissen. Eine Therapieoptimierung ist möglich durch die Behandlung mit dem löslichen Guanylatcylase (sGC)-Stimulator Vericiguat.